Stock A128940 HANMI PHARM. CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Hanmi Pharm. Co., Ltd.

Equities

A128940

KR7128940004

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
316,500 KRW +0.80% Intraday chart for Hanmi Pharm. Co., Ltd. -2.31% -10.21%
05-08 Invion Partners with Hanlim Pharma for Glioblastoma Treatment MT
05-01 Hanmi Pharm Q1 Profit Surges 27.5%, Sales Up 11.8% MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allergic Rhinitis Pipeline, Clinical Trials, Key Companies
AQ
Allergic Rhinitis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)
AQ
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib First-in-Class Candidate for the Treatment of Intermediate Dry AMD
AQ
Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type
AQ
Hanmi Science : Pharmaceutical expects U.S. FDA approval for 2 new drugs
AQ
Hanmi Science : presents solution package strategy to potentially overcome COVID-19 at the 39th JP Morgan Healthcare Conference
AQ
Hanmi Pharm : FDA Grants Fast Track Designation for Hanmi LAPSTriple Agonist
AQ
HanmiPharm : Hanmi/Beijing Hanmi and Innovent Enter into a Global Strategic Partnership to Co-develop a Novel Immuno-oncology Bispecific Antibody
BU
HanmiPharm : Hanmi Pharmaceutical Enters into an Exclusive License Agreement with Genentech for a Novel Oral RAF Inhibitor
BU
HanmiPharm : ZAI Lab and Hanmi Execute a License Agreement to Develop Novel EGFR Targeted Therapy for Lung Cancer in China
BU
HanmiPharm : Hanmi Pharmaceutical Signs an Exclusive License Agreement with Janssen Pharmaceuticals, Inc. to Develop a Novel Biologic for Treatment of Diabetes and Obesity
BU
HanmiPharm : Hanmi Pharmaceutical: Efpeglenatide (GLP-1 Analog), the Promising Potential for Anti-Diabetes/Anti-Obesity Treatment as Once Weekly up to Once Monthly
BU
HanmiPharm : Hanmi Pharmaceutical : Once-Weekly Insulin Combination, ‘LAPSInsulin Combo’, Suggests a New Diabetes Therapeutic Option
BU
HanmiPharm : Hanmi Pharmaceutical to Present Its New Diabetes Drugs Including Quantum Project at 2015 ADA Scientific Sessions
BU
HanmiPharm : Hanmi Pharmaceutical ‘HM61713’ Demonstrated the Effect of Tumor Volume Reduction
BU
HanmiPharm : Hanmi Pharmaceutical to Present Its New Targeted Lung Cancer Drug 'HM61713' at 2015 ASCO Annual Meeting
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A128940 Stock
  4. News Hanmi Pharm. Co., Ltd.
  5. Press Releases